B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co
4.5 (762) · $ 18.00 · In stock
Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients. MELSUNGEN, Germany and MONMOUTH JUNCTION, N.J., March 2, 2021 /PRNewswire/ — B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation […]
Organization
biohaveninvestorpresenta
In this image released on Tuesday, March 2, 2021, the OMNI® extracorporeal platform is intended to perform continuous blood purification treatments and therapeutic plasma exchange. The OMNI® in combination with OMNIset®* disposable
Digital Diabetes Management Market Size, Trends & Forecast
THE Arab Bank for Economic Development in Africa (BADEA) RECEIVES
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co
Newsroom
Where do lawsuits against B. Braun over cancer-causing chemical stand?
In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum
CS Medical and B. Braun Partnership: Advancing Vascular Intervention Therapy – CS Medical Group
